You Lu

ORCID: 0000-0001-9396-5562
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Virus-based gene therapy research
  • Cancer-related Molecular Pathways
  • Cancer Genomics and Diagnostics
  • Genetics, Bioinformatics, and Biomedical Research
  • Lung Cancer Treatments and Mutations
  • Parasites and Host Interactions
  • Gene expression and cancer classification
  • HER2/EGFR in Cancer Research
  • Genetic factors in colorectal cancer
  • Ubiquitin and proteasome pathways
  • Immunodeficiency and Autoimmune Disorders
  • Cancer Immunotherapy and Biomarkers
  • Cancer-related gene regulation
  • Genetics, Aging, and Longevity in Model Organisms
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Multiple Myeloma Research and Treatments
  • Gastric Cancer Management and Outcomes
  • Advanced Proteomics Techniques and Applications
  • DNA Repair Mechanisms
  • RNA Interference and Gene Delivery
  • Cancer, Lipids, and Metabolism
  • Microtubule and mitosis dynamics
  • Advanced Breast Cancer Therapies
  • Protein Degradation and Inhibitors
  • Medical Research and Treatments

Tulane University
2025

Shanghai Tenth People's Hospital
2022-2024

Tongji University
2022-2024

Chinese Academy of Medical Sciences & Peking Union Medical College
2010-2022

Fujian Medical University
2022

Union Hospital
2022

State Key Laboratory of Biotherapy
2020

Sichuan University
2020

Peking University
2001-2015

Peking University Cancer Hospital
2001-2015

Abstract Background There is inconclusive evidence to suggest that the expression of programmed cell death ligand 1 (PD-L1) a putative predictor response EGFR-TKI therapy in advanced EGFR-mutant non-small lung cancer (NSCLC). We evaluated heterogeneity PD-L1 primary site and metastatic lymph nodes analyze association between for patients treated with EGFR-TKI. Methods This study reviewed 184 NSCLC EGFR mutations who received first-generation as first-line treatment from 2020 2021 at Shanghai...

10.1186/s12931-024-02858-3 article EN cc-by Respiratory Research 2024-06-05

Abstract Previous cytogenetic investigations have revealed frequent deletions and ocher unbalanced structural rearrangements of 3p in human malignant mesothelioma. We performed a restriction fragment length polymorphism analysis by using the polymerase chain reaction primer sets for seven DNA markers to examine loss heterozygosity (LOH) from 25 mesotheliomas. Among 24 cases informative at one or more loci, 15 (62.5%) exhibited LOH with least marker. Deletion mapping these tumors indicates...

10.1002/gcc.2870090114 article EN Genes Chromosomes and Cancer 1994-01-01

Abstract: Nuclear protein in testis (NUT) carcinoma (NUT-C) is an exceedingly rare and aggressive squamous tumor characterized by acquired rearrangement of the NUT gene involving NUTM1 (Nut midline carcinoma, family member 1, NUT) encoding nuclear on 15q14. As a tumor, there little information available clinicopathologic molecular cytogenetic findings NMC. We herein reported case 69-year-old man diagnosed with lung NMC chromosomal region 15q14 harboring gene. It was exceptionally for...

10.21037/acr-19-168 article EN AME Case Reports 2020-10-01

Objective Gastric cancer (GC) is a typical type of inflammation‐related tumor. The p42.3 gene shown to be highly expressed in GC, but its association with gastritis remains unknown. We aimed explore the relationship between gastric inflammation and vitro vivo . Methods Normal epithelial cells (GES‐1) were treated Helicobacter pylori (H. pylori) tumor necrosis factor (TNF)‐α. Total cell mRNA protein extracted collected, polymerase chain reaction Western blot performed determine relative...

10.1111/1751-2980.12282 article EN Journal of Digestive Diseases 2015-08-28

Type 2 diabetes mellitus (T2DM) is the most common metabolic disease and characterized by sustained hyperglycemia. The impact of T2DM on survival lung cancer patients remains controversial. aim this study was to investigate associations type with mortality.From January 2019 2020, 228 non-small cell (NSCLC) staging earlier than IIIA were included.In our study, we found that overall (OS) progression-free (PFS) longer non-diabetes group. Diagnosed associated prognosis after adjusting for age...

10.3390/jcm12010321 article EN Journal of Clinical Medicine 2022-12-31

Abstract Aromatase inhibitors have proven to be highly effective in both therapy and prevention of ER+ breast cancer. Vorozole (R83842), a high affinity competitive inhibitor aromatase (similar letrozole anastrozole) showed strong activity early clinical trials against Furthermore, vorozole was the cancers MNU-mammary cancer model (Lubet, et al., Carcinogenesis 19, 1345, 1998). In present study, rats bearing mammary induced by MNU were exposed (1.25 mg/kg BW/day) for 5 days. Global gene...

10.1158/0008-5472.sabcs11-p3-10-02 article EN Cancer Research 2011-12-01

Point mutations of p21 proteins were constructed by oligonucleotide-directed mutagenesis the v-rasH oncogene, which substituted amino acid residues within nucleotide-binding consensus sequence, GXG GXGK. When glycine residue at position 10, 13, or 15 was with valine, viral rasH product lost its GTP-binding and autokinase activities. Other substitutions 33, 51, 59 did not impair binding activity. G418-resistant NIH 3T3 cell lines derived transfection constructs obtained inserting mutant...

10.1128/mcb.7.9.3092-3097.1987 article EN Molecular and Cellular Biology 1987-09-01
Coming Soon ...